Esperion(US:ESPR)2025-07-03 08:17Company Overview & Strategy - Esperion is evolving into a global cardiometabolic biotech, advancing the CLEAR Outcomes trial and pre-clinical pipeline assets [6] - The company restructured and financed in 2021 to reduce cost burn and strengthen the cash balance [9] - Esperion launched two approved drugs in Q2 2020 in the U S, with strong IP protection anticipated until mid-2031 [9] Market & Products - Nearly 80% of very high-risk patients in the U S did not meet guideline-recommended LDL-C goals [18] - 8.7 million patients in the U S don't reach their LDL-C goals despite taking a statin, while 9.6 million with high LDL-C are not on statins [18] - Up to 20% of people who could be treated with a statin experience statin intolerance [18] - NEXLETOL & NEXLIZET are safe & well-tolerated oral options for LDL-C lowering [30] Financial Performance & Outlook - Q1 2022 U S revenue was $13.4 million [35] - Esperion has >$1.2 billion in potential future ex-U S collaboration milestones from Daiichi Sankyo & Otsuka [67] - Esperion's Q1 2022 cash, cash equivalents, restricted cash & investment securities available-for-sale totaled $268.5 million [67] Clinical Development - The CLEAR Outcomes trial is approaching 100% MACE accumulation in 2H 2022, with top-line results anticipated in Q1 2023 [43] - Over 14,000 patients in 32 countries are fully enrolled in the CLEAR Outcomes trial [44]